Search research articles
Contact Us
Filters
Showing results (21-30 of 333) with videos related to
Page
of 34
Sort By:
Clinical Therapeutics
|
January 7, 1998
Improving health care outcomes through reallocation of health care expenditures
P C Langley
Innovations in Pharmacy
|
May 19, 2021
Tracking and Reporting Outcomes in Medical Marijuana: Establishing Condition Specific State Level Registries
Paul C Langley
Innovations in Pharmacy
|
May 19, 2021
Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy
Paul C Langley
Innovations in Pharmacy
|
May 19, 2021
Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies
Paul C Langley
Innovations in Pharmacy
|
May 19, 2021
The Great I-QALY Disaster
Paul C Langley
Innovations in Pharmacy
|
May 19, 2021
Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds
Paul C Langley
Innovations in Pharmacy
|
August 29, 2022
A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
Paul C Langley
Journal of Medical Economics
|
November 10, 2015
The status of modeled claims
Paul C Langley
Pharmacoeconomics
|
March 8, 1996
The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals
P C Langley
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
July 15, 1995
Pharmacoeconomics and the quality of decision-making by pharmacy and therapeutics committees
P C Langley
Page
of 34
Search research articles
Search
Showing results (21-30 of 333) with videos related to
Sort By:
Page
of 34
Clinical Therapeutics
|
January 7, 1998
Improving health care outcomes through reallocation of health care expenditures
P C Langley
Innovations in Pharmacy
|
May 19, 2021
Tracking and Reporting Outcomes in Medical Marijuana: Establishing Condition Specific State Level Registries
Paul C Langley
Innovations in Pharmacy
|
May 19, 2021
Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy
Paul C Langley
Innovations in Pharmacy
|
May 19, 2021
Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies
Paul C Langley
Innovations in Pharmacy
|
May 19, 2021
The Great I-QALY Disaster
Paul C Langley
Innovations in Pharmacy
|
May 19, 2021
Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds
Paul C Langley
Innovations in Pharmacy
|
August 29, 2022
A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
Paul C Langley
Journal of Medical Economics
|
November 10, 2015
The status of modeled claims
Paul C Langley
Pharmacoeconomics
|
March 8, 1996
The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals
P C Langley
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
July 15, 1995
Pharmacoeconomics and the quality of decision-making by pharmacy and therapeutics committees
P C Langley
Page
of 34